Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
Phase of Trial: Phase I/II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs Bintrafusp alfa (Primary) ; Temozolomide (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2019 Planned number of patients changed from 57 to 67.
- 16 May 2019 Planned End Date changed from 15 Jan 2022 to 15 Jan 2024.
- 16 May 2019 Planned primary completion date changed from 15 Jan 2022 to 15 Jan 2023.